

Practitioner's Docket No. MBIO99-057CP4M

USSN: 09/829,495

In the claims:

1-42. (Presently canceled)

43. (New): An antibody or antigen-binding fragment thereof which immunospecifically binds to a TANGO268 antigen, wherein the antibody or antigen-binding fragment thereof comprises at least one variable heavy (VH) chain complementarity determining region (VHCDR1, VHCDR2 and/or VHCDR3) comprising an amino acid sequence selected from the group consisting of:

VHCDR1: SEQ ID NO:61;

VHCDR2: SEQ ID NO:62; and

VHCDR3: SEQ ID NO:63; and

at least one variable light (VL) chain complementarity determining region (VLCDR1, VLCDR2 and/or VLCDR3) comprising an amino acid sequence selected from the group consisting of:

VLCDR1: SEQ ID NO:64;

VLCDR2: SEQ ID NO:65; and

VLCDR3: SEQ ID NO:66.

44. (New): The antibody of claim 43, wherein the antibody is a monoclonal antibody.

45. (New): The antibody of claim 43, wherein the antibody is a human antibody.

46. (New): The antibody of claims 43, wherein the antibody is a humanized antibody.

47. (New): The antibody of claim 43, wherein the antibody is a Fab fragment.

48. (New): The antibody of claim 43, wherein the antibody is a F(ab')<sub>2</sub> fragment.

49. (New): The antibody of claim 43, wherein the antibody is an scFv.

50. (New): The antibody of claim 43, wherein the antibody is conjugated to a therapeutic or drug moiety.

(Page 2 of 5)

Practitioner's Dock t No. MBIO99-057CP4M

USSN: 09/829,495

51. (New): The antibody of claim 43, wherein the antibody is conjugated to a detectable substance.
52. (New): The antibody of claim 51, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.
53. (New): A kit comprising an antibody or fragment thereof as in any one of claims 43 or 51 and instructions for use.
54. (New): A pharmaceutical composition comprising an antibody according to any one of claims 43 or 50 and a pharmaceutically acceptable carrier.
55. (New): An antibody or antigen-binding fragment thereof which immunospecifically binds to a TANGO268 antigen, wherein the antibody or antigen-binding fragment thereof comprises the variable heavy (VH) chain complementarity determining regions (VHCDR1, VHCDR2 and VHCDR3) and the variable light (VL) chain complementarity determining regions (VLCDR1, VLCDR2 and VLCDR3) comprising the following sequences:
- VHCDR1: SEQ ID NO:61;  
VHCDR2: SEQ ID NO:62;  
VHCDR3: SEQ ID NO:63;  
VLCDR1: SEQ ID NO:64;  
VLCDR2: SEQ ID NO:65; and  
VLCDR3: SEQ ID NO:66.
56. (New): The antibody of claim 55, wherein the antibody is a monoclonal antibody.
57. (New): The antibody of claim 55, wherein the antibody is a human antibody.
58. (New): The antibody of claims 55, wherein the antibody is a humanized antibody.

(Page 3 of 5)

Practitioner's Docket No. MBIO99-057CP4M

USSN: 09/829,495

59. (New): The antibody of claim 55, wherein the antibody is a Fab fragment.
60. (New): The antibody of claim 55, wherein the antibody is a F(ab')<sub>2</sub> fragment.
61. (New): The antibody of claim 55, wherein the antibody is an scFv.
62. (New): The antibody of claim 55, wherein the antibody is conjugated to a therapeutic or drug moiety.
63. (New): The antibody of claim 55, wherein the antibody is conjugated to a detectable substance.
64. (New): The antibody of claim 63, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.
65. (New): A kit comprising an antibody or fragment thereof as in any one of claims 55 or 63 and instructions for use.
66. (New): A pharmaceutical composition comprising an antibody according to any one of claims 55 or 62 and a pharmaceutically acceptable carrier.